Binance gains full regulatory approval in Abu Dhabi, operational from January 2026.Binance gains full regulatory approval in Abu Dhabi, operational from January 2026.

Binance Secures Global License, Plans 2026 Abu Dhabi Hub

2025/12/08 20:21
2분 읽기
What to Know:
  • Binance obtains regulatory approval in Abu Dhabi for global operations.
  • Binance to operate under ADGM from January 2026.
  • Enhanced regulatory oversight expected to influence major digital asset markets.

Binance has obtained a global regulatory license in the Abu Dhabi Global Market, with operations set to commence under this framework on January 5, 2026.

This marks a pivotal move for Binance, cementing its regulatory integration in a top financial hub and potentially reshaping global digital asset exchange practices.

Binance has secured a global license from Abu Dhabi Global Market (ADGM) to operate Binance.com under regulated activities starting 5 January 2026.

The license positions Binance as a major global exchange under a unified regulatory framework, boosting its credibility and extending market access beyond the UAE.

Binance Embraces Unified Licensing Strategy in Abu Dhabi

Binance’s acquisition of a unified license under the Abu Dhabi Global Market signals a pivotal shift in regulatory strategy.

This development highlights a unified approach, replacing fragmented local licenses. Key entities include Binance.com, FSRA of ADGM, and His Excellency Ahmed Jasim Al Zaabi. This move aligns with Binance’s ambition to establish a trusted digital-asset ecosystem worldwide.

Abu Dhabi’s Role in Enhancing Binance’s Market Confidence

The immediate market impact includes increased confidence in Binance’s compliance and operational integrity. It underscores Abu Dhabi’s role in financial innovation, attracting global players to its hub.

The financial implications are extensive, with the potential to shift liquidity towards Binance, influencing digital asset trading markets. This regulatory update strengthens Binance’s position in a competitive global exchange landscape.

This event is part of Binance’s broader effort to standardize regulatory compliance, contrasting with its past strategy of obtaining local licenses. Such precedents reinforce ADGM’s commitment to stringent digital-asset oversight.

Historical trends indicate a shift towards consolidated regulation, with other exchanges likely to follow. This may enhance sector stability, providing a blueprint for future regulatory frameworks in the crypto industry.

For more details, visit the Binance official website.

Disclaimer: The information on this website is for informational purposes only and does not constitute financial or investment advice. Cryptocurrency markets are volatile, and investing involves risk. Always do your own research and consult a financial advisor.
시장 기회
GAINS 로고
GAINS 가격(GAINS)
$0.00764
$0.00764$0.00764
-0.39%
USD
GAINS (GAINS) 실시간 가격 차트
면책 조항: 본 사이트에 재게시된 글들은 공개 플랫폼에서 가져온 것으로 정보 제공 목적으로만 제공됩니다. 이는 반드시 MEXC의 견해를 반영하는 것은 아닙니다. 모든 권리는 원저자에게 있습니다. 제3자의 권리를 침해하는 콘텐츠가 있다고 판단될 경우, service@support.mexc.com으로 연락하여 삭제 요청을 해주시기 바랍니다. MEXC는 콘텐츠의 정확성, 완전성 또는 시의적절성에 대해 어떠한 보증도 하지 않으며, 제공된 정보에 기반하여 취해진 어떠한 조치에 대해서도 책임을 지지 않습니다. 본 콘텐츠는 금융, 법률 또는 기타 전문적인 조언을 구성하지 않으며, MEXC의 추천이나 보증으로 간주되어서는 안 됩니다.

추천 콘텐츠

Vàng Cán Mốc Lịch Sử 5.000 USD: Khi Dự Báo Của CEO Bitget Gracy Chen Trở Thành Hiện Thực Và Tầm Nhìn Về Đích Đến 5.400 USD

Vàng Cán Mốc Lịch Sử 5.000 USD: Khi Dự Báo Của CEO Bitget Gracy Chen Trở Thành Hiện Thực Và Tầm Nhìn Về Đích Đến 5.400 USD

Thị trường tài chính toàn cầu vừa chứng kiến một khoảnh khắc lịch sử chấn động: Giá Vàng thế giới [...] The post Vàng Cán Mốc Lịch Sử 5.000 USD: Khi Dự Báo Của
공유하기
Vneconomics2026/02/10 16:26
Why the Bitcoin Boom Is Not Another Tulip Mania

Why the Bitcoin Boom Is Not Another Tulip Mania

Bitcoin is an amazing success story. It was only invented in January of 2009 and was only worth a tiny fraction of a cent for each token. Over just a few years
공유하기
Medium2026/02/10 15:44
Non-Opioid Painkillers Have Struggled–Cannabis Drugs Might Be The Solution

Non-Opioid Painkillers Have Struggled–Cannabis Drugs Might Be The Solution

The post Non-Opioid Painkillers Have Struggled–Cannabis Drugs Might Be The Solution appeared on BitcoinEthereumNews.com. In this week’s edition of InnovationRx, we look at possible pain treatments from cannabis, risks of new vaccine restrictions, virtual clinical trials at the Mayo Clinic, GSK’s $30 billion U.S. manufacturing commitment, and more. To get it in your inbox, subscribe here. Despite their addictive nature, opioids continue to be a major treatment for pain due to a lack of effective alternatives. In an effort to boost new drugs, the FDA released new guidelines for non-opioid painkillers last week. But making these drugs hasn’t been easy. Vertex Pharmaceuticals received FDA approval for its non-opioid Journavx in January, then abandoned a next generation drug after a failed clinical trial earlier this summer. Acadia similarly abandoned a promising candidate after a failed trial in 2022. One possible basis for non-opioids might be cannabis. Earlier this year, researchers at Washington University at St. Louis and Stanford published a study showing that a cannabis-derived compound successfully eased pain in mice with minimal side effects. Munich-based pharmaceutical company Vertanical is perhaps the furthest along in this quest. It is developing a cannabinoid-based extract to treat chronic pain it hopes will soon become an approved medicine, first in the European Union and eventually in the United States. The drug, currently called Ver-01, packs enough low levels of cannabinoids (including THC) to relieve pain, but not so much that patients get high. Founder Clemens Fischer, a 50-year-old medical doctor and serial pharmaceutical and supplement entrepreneur, hopes it will become the first cannabis-based painkiller prescribed by physicians and covered by insurance. Fischer founded Vertanical, with his business partner Madlena Hohlefelder, in 2017, and has invested more than $250 million of his own money in it. With a cannabis cultivation site and drug manufacturing plant in Denmark, Vertanical has successfully passed phase III clinical trials in Germany and expects…
공유하기
BitcoinEthereumNews2025/09/18 05:26